Close Menu

PerkinElmer, Helix GenePrism:Actionable Insights

Apr 02, 2019

PerkinElmer and Helix have launched GenePrism:Actionable Insights, a genetic screening test that they said is the "most comprehensive clinical grade DNA sequencing and interpretation" test currently on the market. The test allows users to learn about their risk for underlying diseases. A user's DNA will be sequenced by Helix and the results will be interpreted by board-certified geneticists at PerkinElmer Genomics using ordered data interpretation network, that firm's proprietary high-throughput software platform. In comparison to other commercial firms that look at a limited number of letters in a gene sequence, GenePrism:Actionable Insights assesses each of 59 genes in its entirety, including BRCA1/2, the partners said. They also noted that PerkinElmer Genomics maintains one of the largest databases of known genetic variations from different ancestries globally providing customers with a more in-depth assessment. 

More Like This

Apr 03, 2020

AmpTec Universal COVID-19 Positive Control IVT RNA EURM-019

AmpTec has released a Universal COVID-19 Positive Control IVT RNA, called EURM-019, to facilitate quality control of the detection of SARS-CoV-2 at core facilities and hospital laboratories. The EURM-019 material consists of single-stranded RNA fragments of the SARS-CoV-2 genome and can also serve as a benchmark to validate SARS-CoV-2 RT-PCR tests kits in development. AmpTec is supplying the control on behalf of the European Commission.

Apr 03, 2020

Thermo Fisher Scientific AcroMetrix Coronavirus 2019 (COVID-19) RNA Control

Thermo Fisher Scientific has launched the Thermo Scientific AcroMetrix Coronavirus 2019 (COVID-19) RNA Control to help validate and monitor COVID-19 molecular diagnostic tests. The non-infectious positive control consists of synthetic RNA transcripts containing the N, S, E, and Orf1ab regions of the SARS-CoV-2 genome. The RNA is ready for reverse transcription, PCR amplification, and detection. The kit contains two vials of RNA at concentrations that will result in low-positive and ultra-low-positive results in most commonly used PCR-based testing methods. The control is available globally as a research-use-only product and is not intended for clinical use.

Apr 03, 2020

Horizon Discovery Arrayed CRISPR Knockout Screening for Primary Human B Cells

Horizon Discovery has added an arrayed CRISPR knockout screening service for primary human B cells to its cell-based screening services. The new B cell screening service will enable researchers to identify genes that affect the function of B cells and examine how this impacts other immune cell types, particularly in infectious diseases, cancer, and auto-immune disorders, such as COVID-19, Burkitt's lymphoma, and multiple sclerosis, the company said.

Apr 03, 2020

Agilent K6460S Clinical Edition TQ LC/MS System

Agilent this week launched the K6460S Clinical Edition TQ LC/MS system, a triple quadrupole liquid chromatography/mass spectrometry system designed to improve in vitro diagnostic workflows in clinical labs. The system is listed as a Class I medical device with the US Food and Drug Administration and includes the clinical edition of Agilent MassHunter software to enable an easy and intuitive submission-to-reporting workflow. TQ LC/MS increases the specificity, selectivity, and accuracy of many clinical diagnostic assays compared to traditional binding assays, Agilent noted in a statement. The platform also received approval from China's National Medical Products Administration in January.

Apr 03, 2020

SensID Control Materials for Qiagen Therascreen PIK3CA RGQ PCR Kits

SensID, a Germany-based provider of controls and reference materials for clinical genomics, has introduced a set of controls for Qiagen's US Food and Drug Administration-approved and CE-IVD marked Therascreen PIK3CA RGQ PCR kits. Qiagen's kit was launched in Europe in February 2020 to aid in the identification of activating PIK3CA mutations in FFPE or blood plasma samples from patients with advanced breast cancer. The kit received FDA approval in 2019 and has been commercialized in the US as a companion diagnostic test for alpelisib (Novartis' Piqray).

SensID and Qiagen collaborated to develop the new control materials, which include 11 clinically actionable PIK3CA mutations estimated to be present in approximately 40 percent of HR+/HER2- advanced breast cancer cases and to confer a greater likelihood of responding positively to PI3K inhibitors. The control set contains seven vials (DNA in buffer) in a format matched to the reaction mixes of the Therascreen kit, and each set provides sufficient materials for about 40 runs, the company said. SensID also offers certified DNA-free human plasma that can be used in conjunction with the sample set, if suitable plasma is not available locally.

Apr 01, 2020

Enpicom ImmunoGenomiX Software V2.0

Dutch bioinformatics firm Enpicom has released version 2.0 of its ImmunoGenomiX (IGX) Platform for the management, analysis, and visualization of T- and B-cell receptor sequencing data. The new version supports single-cell sequencing data in addition to bulk sequencing data. The ability to analyze data from both single-cell and bulk sequencing workflows in tandem provides new opportunities for immunomics research and drug development, the company said. Other new enhancements include the IGX-Compare app, which allows users to compare any two data sets to visualize and prioritize matching clones; and more extensive data support, supporting the upload of readily annotated clone tables from, for instance, 10x Genomics or Adaptive Biotechnologies. The new version also features more clonotype grouping definitions and V/J gene usage plotting.

Mar 31, 2020

Berkeley Lights OptoSeq 3' mRNA Library Kit

Berkeley Lights has launched its OptoSeq 3' mRNA Library kit, which allows users to directly link phenotype to genotype. The kit inculdes reagents, primers, probes, and enzymes to prepare and label individual cells for cDNA sequencing. 

According to the firm, customers can use the library prep kit to capture and link genomic information to single-cell phenotypic data in order to learn more about cellular behavior and ramp up discovery, development, and production of cell-based products. 

Mar 30, 2020

Phase Scientific Phasify Viral RNA Extraction Kit

Phase Scientific, which is headquartered in Hong Kong with R&D and manufacturing facilities in Southern California and mainland China, has globally launched the Phasify Viral RNA Extraction Kit, which purifies and concentrates viral RNA in patient viral transport media samples. Phasify is a proprietary technology developed by Phase Scientific that can concentrate target molecules 10-fold to 100-fold, making them easier to detect. The kit can be used with sample volumes of up to 1 ml, and can produce enhanced viral RNA concentration with flexible elution volume up to 10 µl. According to the company, the kit enables a three- to six-cycle threshold reduction compared to solid phase extraction.

Mar 20, 2020

Asuragen Armored RNA Quant SARS-CoV-2 Control

Asuragen is offering an Armored RNA Quant SARS-CoV-2 Control for use in developing assays in response to the COVID-19 pandemic. The new control material targets the SARS-CoV-2 viral nucleocapsid region and, along with the company's new RNAse P construct, aligns with the US Centers for Disease Control and Prevention- and World Health Organization-recommended diagnostic panel. Asuragen said that armored technology encapsulates the in vitro transcribed RNA in a protective protein coat to resist nuclease degradation, enabling its use as RNA extraction, process quality, and positive diagnostic reference controls.

Mar 20, 2020

LGC SeraCare AccuPlex SARS-CoV-2 Reference Material Kit

LGC SeraCare recently launched the AccuPlex SARS-CoV-2 Reference Material Kit, which contains positive reference material targeting the published US Centers for Disease Control and Prevention and World Health Organization consensus sequences, as well as complementary negative reference material targeting the human RNAse P gene. LGC SeraCare said that its kit is superior to "naked" transcribed RNA which does not evaluate the assay extraction step, and safer than heat-treated infectious samples, and are a valuable tool for clinical laboratories seeking to perform assay installation, verification, and performance monitoring.

Mar 20, 2020

Arima Genomics HiChIP Assay and MAPS Pipeline

Arima Genomics has launched its HiChIP chromatin conformation assay. The assay is built on its Arima-HiC platform and introduces chromatin immunoprecipitation sequencing to provide data on long-range chromatin interactions specifically enriched at genomic locations occupied by proteins of interest.

The firm has also created an optimized version of the Model-based Analysis of Proximity Ligation-Assisted ChIP-seq and HiChIP (MAPS) bioinformatics pipeline to help streamline data analysis.

Mar 20, 2020

Twist Bioscience SARS-CoV-2/COVID-19 NGS Target Enrichment Panel

Twist Bioscience is offering a research-use-only target enrichment panel for viral detection and characterization of SARS-CoV-2, the virus that causes COVID-19, using next-generation sequencing. The panels, comprising synthetic double-stranded DNA probes covering the entire viral genome, can also be used for environmental monitoring and surveillance. Kits are available in three sizes: 2 reactions, 12 reactions, and 96 reactions.

Mar 20, 2020

Oncocyte DetermaIO

Oncocyte said it has completed CLIA Validation for and launched DetermaIO, previously the Insight Genetics IM Score Test. The test is now available for research use within the biopharmaceutical and academic communities. DetermaIO is a gene expression profile test that evaluates the immune microenvironment in biopsies from cancer patients to identify individuals more or less likely to respond to anti-PD-1/PD-L1 immunotherapy.  The test differentiates itself from other immunotherapy diagnostic tests by having the capability to determine if the immune microenvironment is active or quiescent. DetermaIO has the potential to be used to stratify patients in the more than 3,000 PD-1/PD-L1 ongoing clinical trials that are collectively expected to recruit over 500,000 patients, the company said.

Mar 20, 2020

DNAstack COVID-19 Beacon

DNAstack has released Beacon for SARS-CoV-2, the virus that causes COVID-19, to enable the scientific and medical communities to share and discover knowledge about the genetics of the virus in real time. Beacon, which is available here, will allow information about genetic variants to be shared instantly using software that follows an open international standard, the company said.

Researchers can use the new Beacon to discover sequences with specific genetic mutations and map their geographic and evolutionary origins. The platform integrates derivative data from genetic sequencing libraries such as GISAID and links to Nextstrain pathogen evolution visualizations. 

The COVID-19 Beacon is compliant with the Beacon API, an internationally recognized open-source protocol developed by the Global Alliance for Genomic and Health (GA4GH). The system is deployed on Microsoft Azure, a cloud computing platform with global reach and scalability.

Mar 19, 2020

Paragon Genomics CleanPlex SARS-CoV-2 NGS Panel

Paragon Genomics has launched its CleanPlex SARS-CoV-2 Panel for COVID-19 coronavirus detection, tracking, and research through amplicon-based target enrichment for next-generation sequencing applications. According to the firm, the panel covers the entire genome of the SARS-CoV-2 virus responsible for the global COVID-19 pandemic. Paragon said that the panel's four-step workflow converts viral RNA into sequencing-ready libraries within five hours. Powered by Paragon's CleanPlex's technology, versions of the panel are available for both the Illumina and MGI sequencing platforms. 

Paragon is also offering free consultation for researchers interested in designing custom NGS panels for coronavirus research.

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.